Novavax Inc. (NVAX)
Novavax, Inc. (NVAX) H.C. Wainwright 26th Annual Global Investment Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX ) H.C. Wainwright 26th Annual Global Investment Conference September 9, 2024 3:30 PM ET Company Participants Jim Kelly - CFO Bob Walker - Head of R&D Conference Call Participants Vernon Bernardino - H.C.
Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again?
Novavax's stock has been surging this year after announcing news of a collaboration with Sanofi. The company recently reported a profit, but whether it can stay out of the red is still a big question mark.
Novavax Stock Up 9% on FDA Nod for Updated COVID-19 Vaccine
The FDA authorization for NVAX's updated COVID-19 vaccine makes it the only non-mRNA vaccine option in the country.
FDA authorizes Novavax's updated Covid vaccine, paving way for fall rollout
The Food and Drug Administration authorized Novavax's new protein-based Covid vaccine for emergency use in people ages 12 and up. Novavax's vaccine targets the highly contagious omicron subvariant JN.1, which began circulating widely in the U.S. earlier this year.
FDA authorizes Novavax's updated COVID vaccine targeting JN.1 strain
The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot.
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
Novavax's shares are up significantly in 2024. The biotech's upcoming clinical trials could provide another boost.
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It
Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novavax: Staying Long Despite Coming Up Short In Q2
Novavax reported Q2 earnings with a miss on EPS and revenue, causing a drop in share price, but recovered after the earnings call. Novavax is making progress with internal vaccine candidates, Sanofi partnership, and potential market opportunities, despite disappointing Q2 earnings. I provide my thoughts on the quarter, and will highlight a few downside risks that investors should consider.
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. NASDAQ: NVAX is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. Its most significant vaccine, Nuvaxovid, is for COVID-19.
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Novavax, Inc. (NVAX) Q2 2024 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX ) Q2 2024 Results Conference Call August 8, 2024 8:30 AM ET Company Participants Erika Schultz - Senior Director of Investor Relations John Jacobs - President and Chief Executive Officer John Trizzino - President and Chief Operating Officer Dr. Bob Walker - Chief Medical Officer and Interim Head of Research and Development Jim Kelly - Chief Financial Officer and Treasurer Conference Call Participants Roger Song - Jefferies Mayank Mamtani - B. Riley Securities Alec Stranahan - Bank of America Eric Joseph - JPMorgan Operator Good morning, and welcome to Novavax' Second Quarter 2024 Financial Results and Operational Highlights Conference Call.
